Related Experiment Video
Updated: Jun 21, 2026

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
c-Rel is a transcriptional repressor of EPHB2 in colorectal cancer
1Department of General Surgery, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, People's Republic of China.
Abstract:
The receptor tyrosine kinase EPHB2 has recently been identified as a TCF4 transcriptional target that controls the intestinal epithelial architecture through repulsive interactions with Ephrin-B ligands. Many reports have demonstrated that most human colorectal cancers lose EPHB2 expression despite constitutive Wnt activation. Therefore, we investigated the mechanisms that cause EPHB2 down-regulation in colorectal cancer. In this study, we demonstrate that DNA hypermethylation was not responsible for the frequent loss of EPHB2 expression in colorectal cancer. Cloning and functional characterization of the EPHB2 gene 5'-flanking region revealed a potential negative regulatory element in the distal regulatory region. In vitro electrophoretic gel mobility shift and in vivo chromatin immunoprecipitation assays demonstrated that c-Rel directly binds to the putative element. Inhibiting c-Rel activity or knocking down c-Rel expression by RNA interference in colon cancer cells was sufficient to induce EPHB2 expression. Furthermore, transient transfection assays demonstrated that c-Rel over-expression repressed endogenous EPHB2 expression in colon cancer cells. We demonstrate for the first time that c-Rel acts as a transcriptional repressor of EPHB2 and plays an active role in EPHB2 down-regulation in colorectal cancers.
Insights
Colorectal cancers often lose EPHB2 expression. Researchers found that c-Rel represses EPHB2 transcription, explaining this loss and offering new therapeutic targets for colorectal cancer.
Area of Science:
- Molecular Biology
- Oncology
- Cell Biology
Background:
- EPHB2, a receptor tyrosine kinase, regulates intestinal epithelial architecture.
- Loss of EPHB2 expression is common in colorectal cancer despite Wnt pathway activation.
- Mechanisms driving EPHB2 down-regulation in colorectal cancer remain unclear.
Purpose of the Study:
- To investigate the molecular mechanisms responsible for EPHB2 down-regulation in colorectal cancer.
- To identify transcriptional factors involved in controlling EPHB2 expression in colon cancer cells.
Main Methods:
- Analysis of EPHB2 gene 5'-flanking region for regulatory elements.
- Electrophoretic gel mobility shift assays (EMSA) to assess protein-DNA binding.
- Chromatin immunoprecipitation (ChIP) assays to confirm in vivo binding.
- RNA interference (RNAi) to knockdown c-Rel expression.
- Transient transfection assays to evaluate c-Rel's effect on EPHB2 expression.
Main Results:
- DNA hypermethylation does not cause EPHB2 loss in colorectal cancer.
- A negative regulatory element in the EPHB2 5'-flanking region was identified.
- c-Rel was found to directly bind to this regulatory element.
- Inhibition or knockdown of c-Rel increased EPHB2 expression in colon cancer cells.
- Over-expression of c-Rel repressed endogenous EPHB2 expression.
Conclusions:
- c-Rel acts as a transcriptional repressor of the EPHB2 gene.
- c-Rel plays an active role in the down-regulation of EPHB2 in colorectal cancers.
- These findings elucidate a novel mechanism of EPHB2 regulation in cancer and suggest c-Rel as a potential therapeutic target.
Related Concept Videos
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Master Transcription Regulators
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Co-activators and Co-repressors
Co-activators and Co-repressors
Cell Specific Gene Expression
